Efficacy, Safety and Tolerability of a New 10% Intravenous Immunoglobulin for the Treatment of Primary Immunodeficiencies

We report here the results of a phase 3 study to assess the efficacy, safety, and tolerability of GC5107, a new 10% liquid intravenous immunoglobulin (IVIG) in preventing serious bacterial infections in patients with primary immunodeficiency (ClinicalTrials.gov: NCT02783482). Over a 12-month study p...

Descripción completa

Detalles Bibliográficos
Autores principales: Perez, Elena E., Hébert, Jacques, Ellis, Anne K., Alpan, Oral, Lumry, William R., Shapiro, Ralph, Suez, Daniel, Mandujano, J. Fernando, Wasserman, Richard L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8297997/
https://www.ncbi.nlm.nih.gov/pubmed/34305948
http://dx.doi.org/10.3389/fimmu.2021.707463

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8297997/
https://www.ncbi.nlm.nih.gov/pubmed/34305948
http://dx.doi.org/10.3389/fimmu.2021.707463

Ejemplares similares